Developer docs
API playgroundTry for free, no card

Search company profiles

Navigo Proteins GmbH

Full company profile

uuid0009a4e

Namestring
Navigo Proteins GmbH
Legal namestring
Navigo Proteins GmbH
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Navigo Proteins GmbH is a privately held German protein engineering company headquartered on the Weinberg Campus in Halle (Saale), operating two wholly-owned subsidiaries — Navigo Pure and Navigo Precision — and holding minority stakes in two asset vehicles, GAIASO Theranostics and OptigoBio. Navigo Pure delivers affinity chromatography solutions under the Precision Capturing® brand for downstream processing in biotherapeutics manufacturing, while Navigo Precision develops next-generation radiotheranostics and targeted therapies for oncology indications with significant unmet need. The company's core technology is the proprietary Affilin® platform, which produces novel target-binding proteins that combine the specificity and affinity of antibodies with the smaller size and tumor penetration advantages of peptides; Affilin® molecules can be configured as mono-, bi-, or multi-specific ligands and coupled to radioactive isotopes or cytotoxic payloads. The HEAD platform layers Affilin® into preclinical radiopharmaceutical development, and a separate pre-targeting strategy pairs Affilin® with VERAXA's trans-cyclooctene click chemistry to separate tumor binding from radio-conjugation in vivo.

The company generates revenue primarily through technology licensing (Affilin® and HEAD licenses into GAIASO and OptigoBio), strategic R&D collaborations (VERAXA Biotech, SCK CEN, ITM), and contract bioprocessing for biotherapeutics manufacturers, with future royalty potential from successful clinical assets. Its go-to-market is enterprise field sales: a Head of Business Development engages pharma and biotech counterparties directly (BD@navigo-proteins.com), supported by conference presence at BIO International Convention, BIO-Europe, Swiss Biotech Days, BioProcess International Europe and TIDES USA. AI-assisted protein engineering — using Rosetta/PyRosetta, protein language models, and generative AI against proprietary compound libraries — is built into the design workflow. Ownership is described as rooted in a long tradition of German family entrepreneurship, with no disclosed venture capital or private equity funding rounds.

Short descriptiontext

Navigo Proteins GmbH is a privately held German biotech that develops the proprietary Affilin® and HEAD protein platforms, licensing them into radiotheranostics, oncology therapeutics, ophthalmology, and bioprocessing through its Navigo Pure and Navigo Precision subsidiaries and asset vehicles GAIASO Theranostics and OptigoBio.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHalle, Germany
HQ citystring
Halle
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
protein engineering services, radiotheranostic development, affinity chromatography solutions, targeted radioligand therapy, bioprocessing purification platforms
Industry2 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Protein Engineering & Radiotheranostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing
TypeLicensing Royalties
Description

Navigo Proteins licenses its Affilin® and other proprietary technologies to third-party companies including GAIASO Theranostics and OptigoBio through asset vehicle structures. This generates licensing revenue while allowing efficient advancement of promising assets into clinical development.

navigo-proteins.com
2Co-development and R&D Collaboration Agreements
TypeProfessional Services
Description

Strategic R&D collaborations with partners such as VERAXA Biotech and SCK CEN focused on developing novel radiotheranostics. These partnerships likely involve upfront payments, milestone payments, and potential future royalties on successful products.

navigo-proteins.com
3In-house Product Development
TypeOne Time License
Description

Development of proprietary radiopharmaceutical products through Navigo Precision subsidiary targeting significant unmet medical needs in oncology. Products under development aim to deliver best-in-class therapies directly to patients.

navigo-proteins.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Navigo Pure
Description

Drives innovation in affinity chromatography, delivering efficient, scalable, and sustainable bioprocessing solutions for the biotherapeutics industry.

navigo-proteins.com
+2 more records
Core offering1 text field

Navigo Proteins engineers and licenses proprietary Affilin® target-binding proteins and the HEAD radiotheranostic platform for development of targeted cancer therapeutics and diagnostics, while its Navigo Pure subsidiary delivers Precision Capturing® affinity chromatography solutions for biotherapeutics manufacturing. The company monetizes these technologies primarily through technology licensing, strategic R&D co-development agreements, and proprietary product development via its subsidiaries and asset vehicles.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Achieves exceptional tumor-specific accumulation with favorable biodistribution
+2 more records
Product overview1 text field

Navigo Proteins GmbH is a biotech company operating through two core subsidiaries—Navigo Pure and Navigo Precision—along with specialized asset vehicles (GAIASO Theranostics, OptigoBio). Navigo Pure delivers affinity chromatography and Precision Capturing solutions for bioprocessing, while Navigo Precision develops targeted radiotheranostics and therapeutics. The company's proprietary Affilin platform and HEAD platform enable development of novel target-binding proteins for cancer diagnostics and treatment, with technology licensed to asset vehicles for clinical advancement.

Product and service4 records
1Navigo Pure
CategoryBioprocessing / Affinity Chromatography
Description

Wholly-owned subsidiary offering affinity chromatography and Precision Capturing® bioprocessing solutions for efficient, scalable, and sustainable manufacturing of biotherapeutics, targeting biopharmaceutical manufacturers.

2Navigo Precision
CategoryRadiotheranostics / Targeted Therapeutics
Description

Wholly-owned subsidiary developing next-generation targeted radiotheranostics and innovative products aimed at enhancing patient diagnosis, treatment, and quality of life for diseases with significant unmet medical needs, with focus on oncology.

3GAIASO Theranostics
CategoryRadiotheranostics Asset Vehicle
Description

Asset vehicle (minority-held by Navigo) developing radiotheranostic products in oncology, particularly in the area of female cancers, advancing Affilin®-based assets toward clinical development.

4OptigoBio
CategoryOphthalmology Asset Vehicle
Description

Asset vehicle (minority-held by Navigo) developing cutting-edge treatments for vision loss caused by chronic ophthalmic diseases, advancing next-generation intravitreal therapies using Affilin®-based assets.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1SCK CEN
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

Strategic R&D collaboration for preclinical development of next-generation radiotheranostics using Auger-electron emitting radioisotope Terbium-161. Combines Navigo's Affilin® and HEAD platforms with SCK CEN's expertise in radioisotopes and preclinical testing. Focus on multiple undisclosed targets.

navigo-proteins.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-12
Description

Research collaboration to develop novel radioimmunoconjugates for diagnosing and treating challenging cancers. Combines Navigo's Affilin® platform with VERAXA's proprietary trans-cyclooctene-based click chemistry technology using a pre-targeting strategy. Affilin® molecules bind to tumor antigens before a radioactive payload is conjugated in vivo.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration in the radiopharmaceutical industry with ITM, a strong player in targeted radioligand therapy. Drives development of Affilins® for targeted radioligand therapy and imaging.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensed technology to GAIASO Theranostics, an asset vehicle company developing radiotheranostic products in oncology, particularly female cancers. Company founded with support and partial ownership of Navigo Proteins.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensed technology to OptigoBio, an asset vehicle company developing cutting-edge treatments for vision loss caused by chronic ophthalmic diseases. Company founded with support and partial ownership of Navigo Proteins.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK/US clinical-stage biotech developing bicyclic peptide conjugates for targeted oncology, including partnerships with major pharma. Comparable to Affilin's hybrid antibody-peptide concept and its application to cytotoxic conjugates and radioisotope delivery.

TypeBroad incumbent
Description

Global bioprocessing leader offering chromatography resins, systems, and services for biotherapeutics manufacturing. Overlaps with Navigo Pure's Precision Capturing affinity chromatography offering.

TypeDirect peer
Description

Swiss/Italian biotech using antibody fragment-based targeted therapeutics (L19, F16) for oncology, with strong radiopharmaceutical development programs. Closely comparable targeting-ligand approach for radiotheranostics and oncology.

TypeBroad incumbent
Description

Major supplier of chromatography resins and columns for biopharmaceutical manufacturing. Directly comparable to Navigo Pure's Precision Capturing affinity chromatography technology.

TypeDirect peer
Description

Swiss clinical-stage biotech developing DARPin® engineered alternative scaffold proteins for targeted therapeutics. Most direct peer given similar non-antibody scaffold strategy, modularity, and applicability to radiopharmaceutical and oncology applications.

TypeEmerging player
Description

Swiss biotech developing site-specific antibody-drug conjugates using novel linker technology. Comparable emerging biotech with innovative protein-based therapeutic platform targeting oncology applications.

TypeBroad incumbent
Description

US life science tools company with significant chromatography, protein purification, and analytical instrument offerings. Overlaps with Navigo Pure's bioprocessing and protein analytics capabilities.

TypeBroad incumbent
Description

German-headquartered bioprocessing equipment and consumables supplier, including chromatography solutions. Comparable to Navigo Pure's bioprocessing business and competes in downstream processing for biologics manufacturers.

TypeDirect peer
Description

German radiopharmaceutical company and direct Navigo partner. Develops targeted radioligand therapies and imaging agents, making it both a commercial counterpart and a customer for Navigo's Affilin targeting ligands.

103B Pharmaceuticals
TypeDirect peer
Description

German biotech developing peptide-based targeting ligands for radiopharmaceuticals and other therapeutic applications. Comparable in technology (small targeting proteins/peptides), geographic base, and radiotheranostic focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Navigo Proteins GmbH

Biopharmaceutical Protein Engineering & Radiotheranosticsnavigo-proteins.com

Navigo Proteins GmbH is a privately held German biotech that develops the proprietary Affilin® and HEAD protein platforms, licensing them into radiotheranostics, oncology therapeutics, ophthalmology, and bioprocessing through its Navigo Pure and Navigo Precision subsidiaries and asset vehicles GAIASO Theranostics and OptigoBio.

What Navigo Proteins GmbH does

Navigo Proteins GmbH is a privately held German protein engineering company headquartered on the Weinberg Campus in Halle (Saale), operating two wholly-owned subsidiaries — Navigo Pure and Navigo Precision — and holding minority stakes in two asset vehicles, GAIASO Theranostics and OptigoBio. Navigo Pure delivers affinity chromatography solutions under the Precision Capturing® brand for downstream processing in biotherapeutics manufacturing, while Navigo Precision develops next-generation radiotheranostics and targeted therapies for oncology indications with significant unmet need. The company's core technology is the proprietary Affilin® platform, which produces novel target-binding proteins that combine the specificity and affinity of antibodies with the smaller size and tumor penetration advantages of peptides; Affilin® molecules can be configured as mono-, bi-, or multi-specific ligands and coupled to radioactive isotopes or cytotoxic payloads. The HEAD platform layers Affilin® into preclinical radiopharmaceutical development, and a separate pre-targeting strategy pairs Affilin® with VERAXA's trans-cyclooctene click chemistry to separate tumor binding from radio-conjugation in vivo.

The company generates revenue primarily through technology licensing (Affilin® and HEAD licenses into GAIASO and OptigoBio), strategic R&D collaborations (VERAXA Biotech, SCK CEN, ITM), and contract bioprocessing for biotherapeutics manufacturers, with future royalty potential from successful clinical assets. Its go-to-market is enterprise field sales: a Head of Business Development engages pharma and biotech counterparties directly (BD@navigo-proteins.com), supported by conference presence at BIO International Convention, BIO-Europe, Swiss Biotech Days, BioProcess International Europe and TIDES USA. AI-assisted protein engineering — using Rosetta/PyRosetta, protein language models, and generative AI against proprietary compound libraries — is built into the design workflow. Ownership is described as rooted in a long tradition of German family entrepreneurship, with no disclosed venture capital or private equity funding rounds.

Navigo Proteins GmbH firmographics

Firmographics
Name
Navigo Proteins GmbH
Legal name
Navigo Proteins GmbH
Website
https://navigo-proteins.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Navigo Proteins GmbH is a privately held German biotech that develops the proprietary Affilin® and HEAD protein platforms, licensing them into radiotheranostics, oncology therapeutics, ophthalmology, and bioprocessing through its Navigo Pure and Navigo Precision subsidiaries and asset vehicles GAIASO Theranostics and OptigoBio.
Ownership category
akta.pro rank

Navigo Proteins GmbH industry classification

Industry
Product category
Biopharmaceutical Protein Engineering & Radiotheranostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Protein engineering services
  • Radiotheranostic development
  • Affinity chromatography solutions
  • Targeted radioligand therapy
  • Bioprocessing purification platforms

Where Navigo Proteins GmbH is headquartered

Location

Headquarters

HQ city
Halle
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Navigo Proteins GmbH business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Licensing: Navigo Proteins licenses its Affilin® and other proprietary technologies to third-party companies including GAIASO Theranostics and OptigoBio through asset vehicle structures. This generates licensing revenue while allowing efficient advancement of promising assets into clinical development.
  2. Co-development and R&D Collaboration Agreements: Strategic R&D collaborations with partners such as VERAXA Biotech and SCK CEN focused on developing novel radiotheranostics. These partnerships likely involve upfront payments, milestone payments, and potential future royalties on successful products.
  3. In-house Product Development: Development of proprietary radiopharmaceutical products through Navigo Precision subsidiary targeting significant unmet medical needs in oncology. Products under development aim to deliver best-in-class therapies directly to patients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Navigo Proteins GmbH product offering

Product offering

Core offering

Navigo Proteins engineers and licenses proprietary Affilin® target-binding proteins and the HEAD radiotheranostic platform for development of targeted cancer therapeutics and diagnostics, while its Navigo Pure subsidiary delivers Precision Capturing® affinity chromatography solutions for biotherapeutics manufacturing. The company monetizes these technologies primarily through technology licensing, strategic R&D co-development agreements, and proprietary product development via its subsidiaries and asset vehicles.

Product overview

Navigo Proteins GmbH is a biotech company operating through two core subsidiaries—Navigo Pure and Navigo Precision—along with specialized asset vehicles (GAIASO Theranostics, OptigoBio). Navigo Pure delivers affinity chromatography and Precision Capturing solutions for bioprocessing, while Navigo Precision develops targeted radiotheranostics and therapeutics. The company's proprietary Affilin platform and HEAD platform enable development of novel target-binding proteins for cancer diagnostics and treatment, with technology licensed to asset vehicles for clinical advancement.

Differentiator

Problem solved

Functional benefit

Brands

  • Navigo Pure: Drives innovation in affinity chromatography, delivering efficient, scalable, and sustainable bioprocessing solutions for the biotherapeutics industry.
  • Navigo Precision
  • Precision Capturing®

Products and services

  • Navigo Pure Wholly-owned subsidiary offering affinity chromatography and Precision Capturing® bioprocessing solutions for efficient, scalable, and sustainable manufacturing of biotherapeutics, targeting biopharmaceutical manufacturers.
  • Navigo Precision Wholly-owned subsidiary developing next-generation targeted radiotheranostics and innovative products aimed at enhancing patient diagnosis, treatment, and quality of life for diseases with significant unmet medical needs, with focus on oncology.
  • GAIASO Theranostics Asset vehicle (minority-held by Navigo) developing radiotheranostic products in oncology, particularly in the area of female cancers, advancing Affilin®-based assets toward clinical development.
  • OptigoBio Asset vehicle (minority-held by Navigo) developing cutting-edge treatments for vision loss caused by chronic ophthalmic diseases, advancing next-generation intravitreal therapies using Affilin®-based assets.

Quantifiable outcome

  • Achieves exceptional tumor-specific accumulation with favorable biodistribution
  • +2 more outcomes

Companies that use Navigo Proteins GmbH

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Navigo Proteins GmbH technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Navigo Proteins GmbH partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • SCK CENcoreStrategic or Co-development Partner · 1 April 2025Strategic R&D collaboration for preclinical development of next-generation radiotheranostics using Auger-electron emitting radioisotope Terbium-161. Combines Navigo's Affilin® and HEAD platforms with SCK CEN's expertise in radioisotopes and preclinical testing. Focus on multiple undisclosed targets.
  • VERAXA Biotech AGcoreStrategic or Co-development Partner · 12 December 2024Research collaboration to develop novel radioimmunoconjugates for diagnosing and treating challenging cancers. Combines Navigo's Affilin® platform with VERAXA's proprietary trans-cyclooctene-based click chemistry technology using a pre-targeting strategy. Affilin® molecules bind to tumor antigens before a radioactive payload is conjugated in vivo.
  • ITMmajorStrategic or Co-development PartnerCollaboration in the radiopharmaceutical industry with ITM, a strong player in targeted radioligand therapy. Drives development of Affilins® for targeted radioligand therapy and imaging.
  • GAIASO TheranosticscoreOEM/ Whitelabel/ Licensing PartnerLicensed technology to GAIASO Theranostics, an asset vehicle company developing radiotheranostic products in oncology, particularly female cancers. Company founded with support and partial ownership of Navigo Proteins.
  • OptigoBiocoreOEM/ Whitelabel/ Licensing PartnerLicensed technology to OptigoBio, an asset vehicle company developing cutting-edge treatments for vision loss caused by chronic ophthalmic diseases. Company founded with support and partial ownership of Navigo Proteins.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Navigo Proteins GmbH competitors and assessment

Company assessment

Direct peers

  • Bicycle Therapeutics: UK/US clinical-stage biotech developing bicyclic peptide conjugates for targeted oncology, including partnerships with major pharma. Comparable to Affilin's hybrid antibody-peptide concept and its application to cytotoxic conjugates and radioisotope delivery.
  • Philogen: Swiss/Italian biotech using antibody fragment-based targeted therapeutics (L19, F16) for oncology, with strong radiopharmaceutical development programs. Closely comparable targeting-ligand approach for radiotheranostics and oncology.
  • Molecular Partners: Swiss clinical-stage biotech developing DARPin® engineered alternative scaffold proteins for targeted therapeutics. Most direct peer given similar non-antibody scaffold strategy, modularity, and applicability to radiopharmaceutical and oncology applications.
  • ITM Isotope Technologies Munich: German radiopharmaceutical company and direct Navigo partner. Develops targeted radioligand therapies and imaging agents, making it both a commercial counterpart and a customer for Navigo's Affilin targeting ligands.
  • 3B Pharmaceuticals: German biotech developing peptide-based targeting ligands for radiopharmaceuticals and other therapeutic applications. Comparable in technology (small targeting proteins/peptides), geographic base, and radiotheranostic focus.

Broad incumbents

  • Cytiva (Danaher): Global bioprocessing leader offering chromatography resins, systems, and services for biotherapeutics manufacturing. Overlaps with Navigo Pure's Precision Capturing affinity chromatography offering.
  • Tosoh Bioscience: Major supplier of chromatography resins and columns for biopharmaceutical manufacturing. Directly comparable to Navigo Pure's Precision Capturing affinity chromatography technology.
  • Bio-Rad Laboratories: US life science tools company with significant chromatography, protein purification, and analytical instrument offerings. Overlaps with Navigo Pure's bioprocessing and protein analytics capabilities.
  • Sartorius: German-headquartered bioprocessing equipment and consumables supplier, including chromatography solutions. Comparable to Navigo Pure's bioprocessing business and competes in downstream processing for biologics manufacturers.

Emerging players

  • Araris Biotech: Swiss biotech developing site-specific antibody-drug conjugates using novel linker technology. Comparable emerging biotech with innovative protein-based therapeutic platform targeting oncology applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Navigo Proteins GmbH social profiles

Digital presence

Navigo Proteins GmbH financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Navigo Proteins GmbH leadership team

Management profile

Number of profiles

Profiles14 records

Navigo Proteins GmbH subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Navigo Proteins GmbH funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Navigo Proteins GmbH M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Navigo Proteins GmbH

What does Navigo Proteins GmbH do?

Navigo Proteins engineers and licenses proprietary Affilin® target-binding proteins and the HEAD radiotheranostic platform for development of targeted cancer therapeutics and diagnostics, while its Navigo Pure subsidiary delivers Precision Capturing® affinity chromatography solutions for biotherapeutics manufacturing. The company monetizes these technologies primarily through technology licensing, strategic R&D co-development agreements, and proprietary product development via its subsidiaries and asset vehicles.

Is Navigo Proteins GmbH a public or private company?

Navigo Proteins GmbH is a private company. It is classified as family owned and is currently operating.

When was Navigo Proteins GmbH founded?

Navigo Proteins GmbH was founded in 2017. It employs 51 to 100 people.

Where is Navigo Proteins GmbH based?

Navigo Proteins GmbH is headquartered in Halle, Germany, in the Europe region.

How does Navigo Proteins GmbH make money?

Three revenue lines are on record. Technology Licensing is the primary driver. The others are co-development and R&D Collaboration Agreements and in-house Product Development.

Who are Navigo Proteins GmbH's main competitors?

Direct peers on record are Bicycle Therapeutics, Philogen, Molecular Partners, ITM Isotope Technologies Munich and 3B Pharmaceuticals. Broad incumbents are Cytiva (Danaher), Tosoh Bioscience, Bio-Rad Laboratories and Sartorius. Araris Biotech is listed as an emerging player.

Does Navigo Proteins GmbH have an API?

No public API is recorded for Navigo Proteins GmbH.

What industry is Navigo Proteins GmbH in?

Navigo Proteins GmbH's product category is Biopharmaceutical Protein Engineering & Radiotheranostics. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals